Analyzing Sequential IPV and OPV Administration

The question asks to identify the statement that is NOT correct regarding the sequential administration of Inactivated Polio Vaccine (IPV) and Oral Polio Vaccine (OPV).

Why Statement C is Incorrect

Statement 3 claims that "Intestinal mucosal immunity is lost due to IPV administration". This statement is factually incorrect.

• IPV (Inactivated Polio Vaccine): Primarily induces humoral immunity (antibodies in the blood). It contains killed poliovirus and does not replicate in the gut.
• OPV (Oral Polio Vaccine): Contains live, attenuated poliovirus. It induces both humoral immunity and strong intestinal mucosal immunity because it replicates in the gut lining, mimicking natural infection and triggering a local immune response.
• Role of IPV: IPV does not actively cause the *loss* of intestinal mucosal immunity. Instead, it simply does not provide significant mucosal immunity itself. Relying solely on IPV would lead to inadequate mucosal protection, but its administration does not equate to the destruction or loss of existing mucosal immunity. Sequential schedules use OPV to provide this crucial mucosal immunity.

Therefore, the assertion that IPV administration leads to the *loss* of intestinal mucosal immunity is inaccurate.

Evaluating Other Statements

• Statement 1 (Cost-effectiveness): While IPV is more expensive than OPV, sequential strategies can be cost-effective by significantly reducing cases of paralysis and VAPP, potentially lowering overall healthcare costs in the long run, especially in resource-limited settings. This statement is plausible.
• Statement 2 (VAPP Reduction): Combining IPV and OPV, particularly in sequential schedules, is a recognized strategy to reduce the risk of Vaccine Associated Paralytic Polio (VAPP), as it decreases the number of OPV doses needed while still providing protection. This statement is considered correct.
• Statement 4 (Optimized Immunogenicity): Sequential schedules aim to leverage the benefits of both vaccines. IPV provides robust systemic (humoral) immunity, while OPV contributes significantly to gut mucosal immunity. Combining them can offer comprehensive protection, potentially optimizing both aspects. This statement is generally considered correct.

Conclusion

The statement that is NOT correct is the one claiming that IPV administration causes the loss of intestinal mucosal immunity. IPV primarily stimulates humoral immunity and does not confer strong mucosal immunity, but it does not actively destroy or cause the loss of this immunity.